Abstract |
The substituted benzimidazoles are a new class of drugs with a unique antisecretory action. These agents have great potential for treatment of acid-peptic disease because they produce substantial, long-lasting inhibition of gastric acid secretion by inhibiting gastric H+,K+-ATPase in the gastric parietal cell. Clinical trials of omeprazole, a substituted benzimidazole, indicate that it is safe and effective for short-term treatment of patients with duodenal or gastric ulcer, and it is highly effective for long-term treatment of patients with Zollinger-Ellison syndrome.
|
Authors | K E McArthur, R T Jensen, J D Gardner |
Journal | Annual review of medicine
(Annu Rev Med)
Vol. 37
Pg. 97-105
( 1986)
ISSN: 0066-4219 [Print] United States |
PMID | 3010811
(Publication Type: Clinical Trial, Comparative Study, Journal Article)
|
Chemical References |
- Anti-Ulcer Agents
- Benzimidazoles
- Adenosine Triphosphatases
- H(+)-K(+)-Exchanging ATPase
- Omeprazole
|
Topics |
- Adenosine Triphosphatases
(antagonists & inhibitors)
- Anti-Ulcer Agents
(administration & dosage, adverse effects, therapeutic use)
- Benzimidazoles
(administration & dosage, adverse effects, therapeutic use)
- Clinical Trials as Topic
- Duodenal Ulcer
(drug therapy)
- Gastric Acid
(metabolism)
- H(+)-K(+)-Exchanging ATPase
- Humans
- Omeprazole
- Parietal Cells, Gastric
(enzymology)
- Peptic Ulcer
(drug therapy)
- Stomach Ulcer
(drug therapy)
- Zollinger-Ellison Syndrome
(drug therapy)
|